aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 International Conference
17. Mai 2018 07:30 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 17, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate Restructuring
14. Mai 2018 06:45 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)
27. November 2017 08:00 ET
|
aTyr Pharma, Inc.
– Second Physiocrine-based therapeutic candidate enters the clinic – – Top-line data expected in 2Q 2018 – – iMod.Fc (ATYR1923) to target interstitial lung diseases with an immune component – SAN...
aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update
14. November 2017 16:05 ET
|
aTyr Pharma, Inc.
- Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter - - Selection of antibody for ORCA program on-track for this quarter - SAN DIEGO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- aTyr...
aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline
14. August 2017 16:05 ET
|
aTyr Pharma Inc.
– Resolaris Demonstrated Favorable Safety Profile in Rare Muscular Dystrophy Patients in Extension Studies –– iMod.Fc Program for Interstitial Lung Disease (ILD) on Track to Commence Phase 1 Clinical...
aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar
15. Mai 2017 08:00 ET
|
aTyr Pharma Inc.
- Poster Presentations to Explore Potential of Augmenting Resokine Pathway in Severe, Rare Pulmonary Diseases with an Immune or Fibrotic Component - - Conference Call and Webcast Featuring Guest...